Ipsen, Université de Montréal and IRICoR are excited to announce that Ipsen has exercised its option to acquire exclusive rights to a pre-clinical stage program with potential oncology applications. This license agreement, which was established in May 2020, will enable Ipsen to assume all development activities and commercialization of the drug candidate globally. In return for their efforts, the Université de Montréal will receive an upfront payment and will be eligible for additional development and commercial milestones, as well as royalties on net sales.
At Ipsen, we are thrilled to be partnering with Amgen to explore the potential of an investigational treatment for a variety of solid tumors and hematological cancers. We believe that through our collaboration, we can unlock great possibilities for patients and their families. Christelle Huguet, SVP, Head of REED, Research, External Innovation & Early Development at Ipsen, is excited to take this project forward and make a positive impact in the fight against cancer.
Ipsen, Université de Montréal and IRICoR are excited to announce an expansion of their strategic partnership through a new multi-year collaboration and option agreement for two discovery-stage programs in oncology. The Institute for Research in Immunology and Cancer (IRIC) at the Université de Montréal will be responsible for the identification, synthesis, and advancement of high-quality therapeutic compounds up to the drug candidate stage. In return, Ipsen will pay the Université de Montréal an upfront payment and research funding. Upon completion of the drug candidate stage, Ipsen will have the option to further develop and commercialize the drug candidates globally, with further payments and mid-single to low double-digit-tiered royalties for any product commercialized. It is an exciting collaboration that will bring the potential of groundbreaking oncology treatments one step closer to reality.
The Institute for Research in Immunology and Cancer at the Université de Montréal is delighted to announce a new research collaboration with Ipsen, a global leader in oncology. This partnership is aimed at driving the development of a promising molecule, offering hope for those whose current standards of care are insufficient. We are confident in the potential of this collaboration to deliver breakthrough therapies and look forward to the impact it will have on patients’ lives.
Claude Larose, VP of Business Development at IRICoR, expressed his excitement for the new exclusive license agreement and strategic partnership with Ipsen to discover new compounds against high-value oncology targets. Initially funded by IRICoR, the program has seen recent advancement under Ipsen’s leadership. Both parties look forward to advancing this new drug-discovery program and bringing potential therapies to patients, creating long-term value for everyone involved.
Ipsen is a global biopharmaceutical company that is transforming lives with medicines in Oncology, Rare Disease and Neuroscience. With total sales of €3.0bn in FY 2022, Ipsen’s medicines are available in over 100 countries. At the core of their innovation lies the company’s research and development efforts, which are based in leading biotechnological and life-science hubs: Paris-Saclay, France; Oxford, U.K.; Cambridge, U.S.; and Shanghai, China. The team behind Ipsen’s success comprises of around 5,000 colleagues worldwide, and the company is listed in Paris (Euronext: IPN) and in the U.S. (ADR: IPSEY).
IRICoR is a pan-Canadian leader in the de-risking of early-stage assets in the field of drug discovery. Designated as a Centre of Excellence in Research and Commercialization (CECR) by the Canadian government and based at the Institute for Research in Immunology and Cancer (IRIC) of the Université de Montréal, IRICoR has been rapidly translating early-stage innovation into potential new therapies since 2008. By combining business-related expertise with access to industry-level drug discovery capabilities, IRICoR offers scientific and commercial projects access to a network of experts and cutting-edge infrastructure, including one of the largest academia-based drug discovery units in Canada. Major funding sources include the federal CECR Program, the Ministère de l’Économie et de l’Innovation du Québec (MEI), and collaborative partnerships with the biopharmaceutical industry. With its pioneering spirit, IRICoR is making powerful strides in the development and commercialization of novel therapies in cancer and rare diseases.
About the Institute for Research in Immunology and Cancer of the Université de Montréal
At the Institute for Research in Immunology and Cancer of the Université de Montréal, innovation is the way forward in the fight against cancer. Located in the heart of the Université de Montréal, this ultra-modern research hub and training centre was founded in 2003 and has already made significant breakthroughs that will shape the future of cancer treatments. With its pioneering approach to research, the IRIC is leading the way in Canada.